{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T22:50:43Z","timestamp":1795215043311,"version":"4.10.3"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bioprojet"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Study Objectives<\/jats:title><jats:p>To asses the long-term safety and efficacy of pitolisant, an histamine H3-receptor antagonist, on narcolepsy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This open-label, single-arm, pragmatic study, recruited adult patients with narcolepsy and Epworth Sleepiness Scale (ESS) score \u226512. After a titration period, patients were treated for up to 1 year with oral pitolisant once-a-day at up to 40 mg. Concomitant stimulants and anti-cataplectic agents were allowed. The primary endpoint was safety; secondary endpoints included ESS, cataplexy, and other diary parameters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients (n = 102, 75 with cataplexy) received pitolisant, for the first time in 73 of them. Sixty-eight patients (51 with cataplexy) completed the 12-month treatment. Common treatment-emergent adverse events were headache (11.8% of patients), insomnia (8.8%), weight gain (7.8%), anxiety (6.9%), depressive symptoms (4.9%), and nausea (4.9%). Seven patients had a serious adverse effect, unrelated to pitolisant except for a possibly related miscarriage. One-third of patients stopped pitolisant, mostly (19.6%) for insufficient benefit. ESS score decreased by 4.6 \u00b1 0.6. Two-thirds of patients completing the treatment were responders (ESS \u2264 10 or ESS decrease \u2265 3), and one third had normalized ESS (\u226410). Complete and partial cataplexy, hallucinations, sleep paralysis, and sleep attacks were reduced by 76%, 65%, 54%, 63%, and 27%, respectively. Pitolisant as monotherapy (43% of patients) was better tolerated and more efficacious on ESS than on add-on, but efficacy was maintained in this last case.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Long-term safety and efficacy of pitolisant on daytime sleepiness, cataplexy, hallucinations, and sleep paralysis is confirmed.<\/jats:p><\/jats:sec>","DOI":"10.1093\/sleep\/zsz174","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T11:20:18Z","timestamp":1564399218000},"source":"Crossref","is-referenced-by-count":76,"title":["Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study"],"prefix":"10.1093","volume":"42","author":[{"given":"Yves","family":"Dauvilliers","sequence":"first","affiliation":[{"name":"Reference National Center for Narcolepsy, Sleep Unit, Department of Neurology, Gui-de-Chauliac Hospital, University of Montpellier 1, Montpellier, INSERM U1061, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2240-2516","authenticated-orcid":false,"given":"Isabelle","family":"Arnulf","sequence":"additional","affiliation":[{"name":"Sleep Disorder Unit, H\u00f4pital la Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Szakacs","sequence":"additional","affiliation":[{"name":"State Health Center, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smaranda","family":"Leu-Semenescu","sequence":"additional","affiliation":[{"name":"Sleep Disorder Unit, H\u00f4pital la Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lecomte","sequence":"additional","affiliation":[{"name":"Bioprojet, 9, rue Rameau, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Scart-Gres","sequence":"additional","affiliation":[{"name":"Bioprojet, 9, rue Rameau, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne-Marie","family":"Lecomte","sequence":"additional","affiliation":[{"name":"Bioprojet, 9, rue Rameau, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Bioprojet, 9, rue Rameau, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"HARMONY III study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Bastuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Dauvilliers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Fran\u00e7oise","family":"Vieccherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Louis","family":"Pepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonia","family":"Quera Salva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Thibault","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Szakacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,29]]},"reference":[{"issue":"27","key":"2019102110292198800_CIT0001","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N Engl J Med."},{"key":"2019102110292198800_CIT0002","doi-asserted-by":"crossref","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","article-title":"Narcolepsy","volume":"3","author":"Kornum","year":"2017","journal-title":"Nat Rev Dis Primers."},{"issue":"12","key":"2019102110292198800_CIT0003","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","article-title":"Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin","volume":"30","author":"Morgenthaler","year":"2007","journal-title":"Sleep."},{"issue":"8","key":"2019102110292198800_CIT0004","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/14656566.2017.1323877","article-title":"Pharmacological management of narcolepsy with and without cataplexy","volume":"18","author":"Kallweit","year":"2017","journal-title":"Expert Opin Pharmacother."},{"issue":"1","key":"2019102110292198800_CIT0005","first-page":"CD003724","article-title":"Antidepressant drugs for narcolepsy","author":"Vignatelli","year":"2008","journal-title":"Cochrane Database Syst Rev."},{"key":"2019102110292198800_CIT0006","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.sleep.2017.03.028","article-title":"Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice","volume":"35","author":"Drakatos","year":"2017","journal-title":"Sleep Med."},{"issue":"1","key":"2019102110292198800_CIT0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2014.10.002","article-title":"Clinical and practical considerations in the pharmacologic management of narcolepsy","volume":"16","author":"Thorpy","year":"2015","journal-title":"Sleep Med."},{"issue":"12","key":"2019102110292198800_CIT0008","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsy185","article-title":"Multiple treatment comparison in narcolepsy: a network meta-analysis","volume":"41","author":"Lehert","year":"2018","journal-title":"Sleep"},{"issue":"1","key":"2019102110292198800_CIT0009","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1124\/jpet.106.111039","article-title":"BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist\/antagonist at the human histamine H3 receptor: preclinical pharmacology","volume":"320","author":"Ligneau","year":"2007","journal-title":"J Pharmacol Exp Ther."},{"issue":"4","key":"2019102110292198800_CIT0010","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1476-5381.2011.01286.x","article-title":"The histamine H3 receptor: from discovery to clinical trials with pitolisant","volume":"163","author":"Schwartz","year":"2011","journal-title":"Br J Pharmacol."},{"issue":"1","key":"2019102110292198800_CIT0011","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","article-title":"An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-\/- mice and patients","volume":"30","author":"Lin","year":"2008","journal-title":"Neurobiol Dis."},{"issue":"11","key":"2019102110292198800_CIT0012","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","article-title":"Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial","volume":"12","author":"Dauvilliers","year":"2013","journal-title":"Lancet Neurol."},{"issue":"3","key":"2019102110292198800_CIT0013","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1474-4422(16)30333-7","article-title":"Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Szakacs","year":"2017","journal-title":"Lancet Neurol."},{"key":"2019102110292198800_CIT0014","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.sleep.2017.01.002","article-title":"The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use","volume":"33","author":"Kollb-Sielecka","year":"2017","journal-title":"Sleep Med."},{"key":"2019102110292198800_CIT0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/NSS.S103462","article-title":"Update on the treatment of narcolepsy: clinical efficacy of pitolisant","volume":"9","author":"Calik","year":"2017","journal-title":"Nat Sci Sleep."},{"key":"2019102110292198800_CIT0016","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2147\/DDDT.S101145","article-title":"Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy","volume":"12","author":"Romigi","year":"2018","journal-title":"Drug Des Devel Ther."},{"issue":"6118","key":"2019102110292198800_CIT0017","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/327117a0","article-title":"Highly potent and selective ligands for histamine H3-receptors","volume":"327","author":"Arrang","year":"1987","journal-title":"Nature."},{"issue":"4","key":"2019102110292198800_CIT0018","doi-asserted-by":"crossref","first-page":"427","DOI":"10.5664\/jcsm.4598","article-title":"Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy","volume":"11","author":"Bogan","year":"2015","journal-title":"J Clin Sleep Med."},{"issue":"3","key":"2019102110292198800_CIT0019","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1389-9457(00)00031-9","article-title":"Long-term efficacy and safety of modafinil (PROVIGIL(\u00ae)) for the treatment of excessive daytime sleepiness associated with narcolepsy","volume":"1","author":"Mitler","year":"2000","journal-title":"Sleep Med."}],"container-title":["Sleep"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsz174\/30023423\/zsz174.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/sleep\/article-pdf\/42\/11\/zsz174\/30251475\/zsz174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/sleep\/article-pdf\/42\/11\/zsz174\/30251475\/zsz174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T03:19:16Z","timestamp":1610680756000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsz174\/5540186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,29]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,7,29]]},"published-print":{"date-parts":[[2019,10,21]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsz174","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,7,29]]},"article-number":"zsz174"}}